small molecule

POMALYST

POMALIDOMIDE

Loss of exclusivityDecember 2031latest FDA-listed patent expiry

CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand name	POMALYST
Active ingredient	POMALIDOMIDE
Strength	2MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	February 2013
Marketing status	RX

Listed patents

Patent	Expires	Type
8828427*PED	December 2031	—
8828427	June 2031	substance, product
9993467*PED	November 2030	—
10555939*PED	November 2030	—
10555939	May 2030	product
9993467	May 2030	product

Regulatory exclusivity

Code	Expires
PED	November 2027
ODE-296	May 2027
ODE-297	May 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BRISTOL MYERS SQUIBB CO